Revance Therapeutics announced a proposed underwritten public offering of $100M of its common stock. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY and the RHA Collection of dermal fillers, support the launch of DAXXIFY into the therapeutics market, as well as for working capital, research and development and general corporate purposes. Barclays is acting as the sole book-running manager for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVNC:
- Revance price target raised to $16 from $15 at Guggenheim
- Revance price target raised to $9 from $8 at Goldman Sachs
- Revance price target lowered to $20 from $42 at Piper Sandler
- Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
- Revance sees FY24 product revenue at least $280M
